In conclusion, the current study, on a biopsy-proven cohort, demonstrated that CK18 is a promising non-invasive biomarker for prediction of disease severity in Taiwanese NASH patients. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.